INS and Hyperglycemia: In the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial, the subtype with the greatest glycaemic response to glargine, a long-acting insulin, compared with standard care was the SIDD subtype, where it decreased occurrence of hyperglycaemia (defined as a mean post-randomisation HbA1c ≥47.5 mmol/mol [6.5%]) by 13% in comparison with the MARD subtype [22].